|
Return
to main press room
page
FOR IMMEDIATE RELEASE
Therion Appoints Richard Woodrich as
Senior Vice President, Business Development
Cambridge, MA, November 17, 1999 - Therion
Biologics Corporation announced today the
appointment of Richard Woodrich to the newly
created position of Senior Vice President of
Business Development. Mr. Woodrich brings to
Therion over 13 years of corporate development
experience in the biotechnology and health care
industries, including expertise gained from
executive management positions at CytoMed, Inc. and
Oculon Corporation.
"Dick's considerable financial knowledge and
strategic partnering skills will be valuable
additions to our management team," said Dennis L.
Panicali, Ph.D., President and Chief Executive
Officer of Therion. "Given his record of
cultivating strong support for both companies and
products, we expect he will play a key role in
advancing the development and commercialization of
our broad portfolio of therapeutic cancer
vaccines." Dr. Panicali noted that Therion
currently has seven vaccine products for the
treatment of cancer in Phase I and Phase II
clinical trials.
Mr. Woodrich joins Therion from his most recent
position as Executive Vice President and Chief
Operating Officer at CytoMed, Inc., where he
oversaw all aspects of corporate development and
business operations. While at CytoMed he was also
instrumental in negotiating an $18 million
licensing and technology asset purchase agreement
with UCB Pharma, Inc., and the acquisition of
CytoMed's development-stage product candidates by
LeukoSite, Inc. Previously, Mr. Woodrich served as
President, Chief Operating Officer and Director of
Oculon Corporation; Chief Financial Officer of
Applied bioTechnology; and Chief Financial Officer
of Millipore Corporation. Mr. Woodrich is a
graduate of Rensselaer Polytechnic Institute and
received his M.B.A. from Harvard Business
School.
Therion Biologics Corporation is engaged in the
development of therapeutic vaccines for cancer and
preventive vaccines for AIDS. Currently, Therion
has seven products in Phase I and Phase II clinical
development for the treatment of major cancers,
including prostate, colorectal and breast cancer
and melanoma. The Company also has a major
corporate alliance with Pasteur Mérieux
Connaught for the development of therapeutic
colorectal cancer and melanoma vaccines. Therion is
headquartered in Cambridge, Massachusetts.
|
Contacts:
Dennis L. Panicali, Ph.D.
President and CEO
Therion Biologics Corporation
(617) 876-7779
|
Sharon Karlsberg or
Wendy Soutsos
Feinstein Kean Healthcare Inc
(617) 577-8110
|
###
Back to
the top
|
|
